Home / Drug shortages / Gemcitabine Hydrochloride Injection

Gemcitabine Hydrochloride Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., a Pfizer Company

The FDA lists a drug shortage record for Gemcitabine Hydrochloride Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 09/11/2025.

Shortage Details

Status
To Be Discontinued
Company
Hospira, Inc., a Pfizer Company
Package NDC
0409-0181-25
Dosage Form
Injection
Presentation
Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0181-25)
Initial Posting
09/11/2025
Revised Date

FDA data resources